Click to login and read the full article.
Don’t have access? Click here to request a demo
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600
Practical Applications Summary
In Oasis or Mirage: Assessing Low-Risk Investing from a Global Perspective, in the Summer 2018 issue of The Journal of Investing, Edward Aw, John Jiang, Gregory Sivin (all of Bessemer Trust), and Aye Soe (of S&P Dow Jones Indices) discuss why low-risk strategies generally outperform market-cap-weighted indices. Such outperformance, the authors state, “gives rise to … low-risk anomalies” that contravene the assumption that a market-weighted portfolio is the optimal way to balance investment risk and return.
To verify the existence of a low-risk anomaly, the authors build a low-risk portfolio of stocks (LRPS) and a low-risk stock portfolio (LRSP), each designed to implement a low-volatility global equity strategy. The authors find that the two portfolios are equally effective in reducing realized volatility relative to a global market-cap-weighted benchmark but that their monthly excess returns over that benchmark are not statistically significant. However, by adding expected returns to the scheme for constructing the low-risk portfolios, the authors find that the modified portfolios outperform to a statistically significant degree.
TOPICS: Security analysis and valuation, equity portfolio management, risk management
- The content is made available for your general information and use and is not intended for trading or other specific investment advice purposes or to address your particular requirements. We do not represent or endorse the accuracy or reliability of any advice, opinion, statement, or other information provided any user of this publication. Reliance upon any opinion, advice, statement, or other information shall also be at your own risk. Independent advice should be obtained before making any such decision. Any arrangements made between you and any third party named in this publication are at your sole risk.
Don’t have access? Click here to request a demo
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600